Contacts
Emma Danks

Emma Danks

Partner

Read More
Suzy Penney

Suzy Davis

Partner

Read More
Contacts
Emma Danks

Emma Danks

Partner

Read More
Suzy Penney

Suzy Davis

Partner

Read More

27 April 2022

Inflexion invests in contract development and manufacturing company Upperton

We have advised private equity firm Inflexion on its substantial investment into contract development and manufacturing organisation Upperton Pharma Solutions ('Upperton').

Upperton specialises in particle engineering for the pharmaceutical industry. The investment from Inflexion, which comes alongside the founder's own investment, will support Upperton in expanding its operations including a larger manufacturing facility and extending its services to support later stages of clinical trials and commercial manufacturing.

We advised on several aspects of the deal with support from our international private equity, patents, employment, and tax teams among others.

Commenting on the deal, Emma Danks, partner and head of the private equity team, said: "This has been a standout transaction for us and we are proud to have advised Inflexion on their investment into Upperton. We were able to demonstrate both our exceptional life sciences expertise alongside our private equity transactional experience for longstanding client Inflexion. The investment promises an exciting new path for Upperton's future."

Andrew Neville, Investment Director at Inflexion added: “Upperton’s expertise allows them to solve complex particle engineering challenges for clients, enabling targeted drug delivery and providing solutions for poorly soluble molecules. There is a growing demand for these services in the market place. With Inflexion’s investment Upperton will support clients further into their clinical trials and onwards to niche commercial manufacture. We're grateful to the Taylor Wessing team for their support on this investment.”

The team was led by partner Emma Danks and senior associate Suzy Davis with support from partners Jonny Bethell, Colin McCall, Emma Oakley, Ann Casey, Liz Wilson, Stuart Broom, Anna Taylor, Sean Nesbitt and Sian Skelton; senior counsel Emma Tait; senior data protection adviser Sally Annereau; senior associates Rhys Bufton, Katie Lewis and Afshan Mallik, and associates Sarah Wallace, Alexander Stones, Charlie Adams, Joe Fallon, Ruth Moffett, Megan Lukins and Katie Fry-Paul.

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

View from above of business team discussing
Private equity

Advising the Theramex management team on its sale by CVC to Carlyle and PAI Partners

30 March 2022

by multiple authors

Click here to find out more
Colleagues discussing
Corporate/M&A & capital markets

Advised Intriva Capital on its acquisition of specialist care provider, Sequence Care Group

5 October 2021

by multiple authors

Click here to find out more
MAIN_Life sciences
Life sciences & healthcare

Advising on major healthcare sale of Nucleus Global to Huntsworth

10 November 2020

by multiple authors

Click here to find out more